GENE ONLINE|News &
Opinion
Blog

Ionis Pharmaceuticals
Ionis Pharmaceuticals’ Factor XI Reduction Proved Effective in Trial
2022-11-07
AstraZeneca Blocks Ionis’ Hypercholesterolemia Treatment from Moving into a Phase 3 Study
2022-09-23
Roche Receives Rights to Ionis’ Antisense Kidney Disease Drug for $55 Million
2022-07-12
AstraZeneca, Ionis’ ATTR Drug Edges Closer to US Approval With Latest Trial Win
2022-06-22
AstraZeneca, Ionis Close $3.5+ Billion Deal for Rare Protein Misfolding Disorder
2021-12-30
Ionis’ Once-Monthly Treatment for Rare Hereditary Disease Achieves Trial Endpoints
2021-03-31
JPM Healthcare Conference: Shape, Korro, and Ionis Present Advances in RNA Therapeutics
2021-01-18
Ionis Initiates Phase 3 Trials for Familial Chylomicronemia Syndrome Treatment
2020-12-06
Intellia Trials CRISPR Drug as Permanent Cure to Fatal Hereditary Disease
2020-10-21
LATEST
Healthcare+ Expo Taiwan 2024 To Become A Global Trade Fair With 600+ Companies Attending
2024-11-29
Cracking the Code: How Genetics Shapes Strength, Power, and Speed in Sports
2024-11-27
Shared Expertise, Shared Vision: Biotech Powerhouses Drive Innovation in This Billion-Dollar Market
2024-11-27
MIRDC Hosts Seminar Featuring Diverse Applications of Plasma Sterilization Technology
2024-11-26
How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando
2024-11-26
PuriBlood Breaks into Brazil: Partners with ABHH and Cromo to Conquer Latin America’s Largest Blood Market
2024-11-26
Merck’s Multi-Billion-Dollar KEYTRUDA Levels Up with Novel Subcutaneous Delivery, Matching IV Efficacy
2024-11-22
EVENT
2024-12-05
8th Healthcare Expo Taiwan
Taipei, Taiwan
Scroll to Top